Their findings suggest that recommendations for Pan-PPAR provide a practical therapeutic approach that improves glycemia and protects the liver in non-obese patients suffering from MASH, liver injury, and T2D [80]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.